PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 27822069-2 2016 Secreted protein acidic and rich in cysteine (SPARC) binds to albumin, suggesting that SPARC plays an important role in tumor uptake of nab-paclitaxel. nab 136-139 secreted protein acidic and cysteine rich Homo sapiens 0-44 32218821-0 2020 The pathological complete response and secreted protein acidic and rich in cysteine expression in patients with breast cancer receiving neoadjuvant nab-paclitaxel chemotherapy. nab 148-151 secreted protein acidic and cysteine rich Homo sapiens 39-83 32548230-2 2020 SPARC overexpression occurs in multiple tumors including pancreatic ductal adenocarcinoma (PDAC) and may predict favorable response to nab-paclitaxel. nab 135-138 secreted protein acidic and cysteine rich Homo sapiens 0-5 27822069-2 2016 Secreted protein acidic and rich in cysteine (SPARC) binds to albumin, suggesting that SPARC plays an important role in tumor uptake of nab-paclitaxel. nab 136-139 secreted protein acidic and cysteine rich Homo sapiens 46-51 27822069-2 2016 Secreted protein acidic and rich in cysteine (SPARC) binds to albumin, suggesting that SPARC plays an important role in tumor uptake of nab-paclitaxel. nab 136-139 secreted protein acidic and cysteine rich Homo sapiens 87-92 27822069-9 2016 Furthermore, patients with high stromal SPARC reactivity in biopsy specimens such as transbronchial lung biopsy or surgical specimens tended to respond better to nab-paclitaxel. nab 162-165 secreted protein acidic and cysteine rich Homo sapiens 40-45 27822069-11 2016 SPARC may be a useful predictive marker for selecting patients likely to respond favorably to nab-paclitaxel treatment. nab 94-97 secreted protein acidic and cysteine rich Homo sapiens 0-5 26832793-0 2016 SPARC-Independent Delivery of Nab-Paclitaxel without Depleting Tumor Stroma in Patient-Derived Pancreatic Cancer Xenografts. nab 30-33 secreted protein acidic and cysteine rich Homo sapiens 0-5 26832793-1 2016 The study goal was to examine the relationship between nab-paclitaxel delivery and SPARC (secreted protein acidic and rich in cysteine) expression in pancreatic tumor xenografts and to determine the antistromal effect of nab-paclitaxel, which may affect tumor vascular perfusion. nab 55-58 secreted protein acidic and cysteine rich Homo sapiens 83-88 26832793-1 2016 The study goal was to examine the relationship between nab-paclitaxel delivery and SPARC (secreted protein acidic and rich in cysteine) expression in pancreatic tumor xenografts and to determine the antistromal effect of nab-paclitaxel, which may affect tumor vascular perfusion. nab 55-58 secreted protein acidic and cysteine rich Homo sapiens 90-134 25947567-12 2015 SPARC resulted up-regulated in both cell lines treated with bevacizumab+nab-paclitaxel. nab 72-75 secreted protein acidic and cysteine rich Homo sapiens 0-5 25368265-1 2014 AIM: To evaluate the predictive value of the expression of the secreted protein acidic and rich in cysteine (SPARC) for nab-paclitaxel in metastatic breast cancer (MBC). nab 120-123 secreted protein acidic and cysteine rich Homo sapiens 63-107 25368265-1 2014 AIM: To evaluate the predictive value of the expression of the secreted protein acidic and rich in cysteine (SPARC) for nab-paclitaxel in metastatic breast cancer (MBC). nab 120-123 secreted protein acidic and cysteine rich Homo sapiens 109-114 23379109-3 2013 Preclinical data indicated an increase of drug accumulation in tumor tissues via nab-paclitaxel administration which appears to be related to direct interaction with albumin-binding proteins including stromal SPARC. nab 81-84 secreted protein acidic and cysteine rich Homo sapiens 209-214 22156929-3 2012 SPARC (secreted protein acidic rich in cysteine) is an albumin-binding matrix-associated protein that is proposed to act as a mechanism for the increased efficacy of a nanoparticle albumin-bound preparation of the antimicrotubular drug Paclitaxel (nab-paclitaxel). nab 248-251 secreted protein acidic and cysteine rich Homo sapiens 0-5 19412420-6 2009 Response to nab-paclitaxel was higher for SPARC-positive patients (10/12, 83%) than SPARC-negative patients (1/4, 25%). nab 12-15 secreted protein acidic and cysteine rich Homo sapiens 42-47 19412420-6 2009 Response to nab-paclitaxel was higher for SPARC-positive patients (10/12, 83%) than SPARC-negative patients (1/4, 25%). nab 12-15 secreted protein acidic and cysteine rich Homo sapiens 84-89 19412420-9 2009 If confirmed in larger studies, treatment with nab-paclitaxel may convert a poor prognosis SPARC-positive patient population into a group with better clinical outcomes. nab 47-50 secreted protein acidic and cysteine rich Homo sapiens 91-96 18766004-9 2008 In these HER2-positive tumors, nab-paclitaxel was equal to or better than polysorbate-based docetaxel in tumors with medium to high SPARC levels (PC3 and HT29), but not in MDA-MB-231/HER2+ tumors with low SPARC expression. nab 31-34 secreted protein acidic and cysteine rich Homo sapiens 205-210 18766004-10 2008 These results demonstrated that the relative efficacy of nab-paclitaxel was significantly higher compared with polysorbate-based docetaxel in HER2-negative tumors (three of three) and in HER2-positive tumors with high levels of SPARC. nab 57-60 secreted protein acidic and cysteine rich Homo sapiens 228-233 8500547-13 1993 In general, however, the level of NaB-induced SPARC expression was considerably reduced in FN cultures correlating with a lower efficiency of CE formation. nab 34-37 secreted protein acidic and cysteine rich Homo sapiens 46-51 8500547-14 1993 Induced SPARC expression was, in large part, dependent on autocrine transforming growth factor-beta (TGF-beta) production since incubation in the presence of NaB+neutralizing antibodies to TGF-beta inhibited both the expression of SPARC by 72% and development of mature CEs. nab 158-161 secreted protein acidic and cysteine rich Homo sapiens 8-13 8500547-14 1993 Induced SPARC expression was, in large part, dependent on autocrine transforming growth factor-beta (TGF-beta) production since incubation in the presence of NaB+neutralizing antibodies to TGF-beta inhibited both the expression of SPARC by 72% and development of mature CEs. nab 158-161 secreted protein acidic and cysteine rich Homo sapiens 231-236 34974029-0 2022 SPARC-mediated long-term retention of nab-paclitaxel in pediatric sarcomas. nab 38-41 secreted protein acidic and cysteine rich Homo sapiens 0-5 34974029-5 2022 Then, we used SPARC-edited Ewing sarcoma cells (A673 line) to demonstrate that SPARC knocked down (KD) cells accumulated significantly less amount of nab-paclitaxel in vitro than SPARC wild type (WT) cells. nab 150-153 secreted protein acidic and cysteine rich Homo sapiens 79-84 34974029-8 2022 SPARC-high PDX responded better to nab-paclitaxel than SPARC-low tumors, although these results should be taken cautiously, given that the PDXs were established from different patients that could have specific determinants predisposing response to paclitaxel. nab 35-38 secreted protein acidic and cysteine rich Homo sapiens 0-5 34974029-9 2022 In addition, SPARC KD Ewing sarcoma xenografts responded better to soluble docetaxel and paclitaxel than to nab-paclitaxel, while SPARC WT ones showed similar response to soluble and albumin-carried drugs. nab 108-111 secreted protein acidic and cysteine rich Homo sapiens 13-18 34974029-10 2022 Overall, our results show that pediatric sarcomas expressing SPARC accumulate nab-paclitaxel for longer periods of time, which could have clinical implications for chemotherapy efficacy. nab 78-81 secreted protein acidic and cysteine rich Homo sapiens 61-66 24753077-5 2014 Primary Ewing sarcoma tumors expressed the transport protein SPARC, previously associated with nab-paclitaxel activity. nab 95-98 secreted protein acidic and cysteine rich Homo sapiens 61-66 24484617-2 2014 The chemotherapeutic agent nanoparticle albumin-encapsulated (NAB)-paclitaxel has been postulated to exploit SPARC expression to target neoplastic cells. nab 62-65 secreted protein acidic and cysteine rich Homo sapiens 109-114 8500547-1 1993 Expression of SPARC (secreted protein acidic and rich in cysteine), a 43-kDa extracellular matrix-associated glycoprotein involved in tissue remodeling, was quantitated during normal human keratinocyte (NHK) growth in culture and as a function of sodium n-butyrate (NaB)-induced differentiation to mature enucleate cornified envelopes (CEs). nab 266-269 secreted protein acidic and cysteine rich Homo sapiens 14-19 8500547-3 1993 After addition of NaB, SPARC expression increased and the pattern of expression shifted to one involving predominantly suprabasal cells (i.e., spinous cells, pre-CEs, and mature CEs). nab 18-21 secreted protein acidic and cysteine rich Homo sapiens 23-28 8500547-10 1993 During NaB-induced NHK differentiation, SPARC intracellular content increased prior to the onset of CE formation (i.e., 2 days after its addition) followed by a period of extracellular accumulation which coincided with the time of maximal CE generation (i.e., Days 4 and 5 after NaB addition). nab 7-10 secreted protein acidic and cysteine rich Homo sapiens 40-45 8500547-10 1993 During NaB-induced NHK differentiation, SPARC intracellular content increased prior to the onset of CE formation (i.e., 2 days after its addition) followed by a period of extracellular accumulation which coincided with the time of maximal CE generation (i.e., Days 4 and 5 after NaB addition). nab 279-282 secreted protein acidic and cysteine rich Homo sapiens 40-45